샘플 요청 목록

 카트 문의
시장보고서
상품코드
1779752

세계의 중추신경계 바이오마커 시장

Central Nervous System Biomarkers
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 376 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 중추신경계 바이오마커 시장은 2030년까지 88억 달러에 달할 전망

2024년에 59억 달러로 추정되는 세계의 중추신경계 바이오마커 시장은 2024-2030년에 CAGR 7.0%로 성장하며, 2030년에는 88억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 안전성 바이오마커는 CAGR 8.0%를 기록하며, 분석 기간 종료까지 46억 달러에 달할 것으로 예측됩니다. 유효성 바이오마커 분야의 성장률은 분석 기간의 CAGR로 6.7%로 추정됩니다.

미국 시장은 16억 달러로 추정, 중국은 CAGR 11.1%로 성장 예측

미국의 중추신경계 바이오마커 시장은 2024년에 16억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 19억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 11.1%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.4%와 6.8%로 예측됩니다. 유럽에서는 독일이 CAGR 4.6%로 성장할 것으로 예측됩니다.

세계의 중추신경계 바이오마커 시장 - 주요 동향과 촉진요인 정리

중추신경계 바이오마커에 대한 수요가 증가하는 이유는 무엇인가?

알츠하이머병, 파킨슨병, 다발성 경화증, 외상성 뇌손상 등 신경질환의 유병률 증가는 중추신경계(CNS) 바이오마커에 대한 수요를 촉진하는 중요한 요인입니다. 이러한 바이오마커는 조기 진단, 질병 진행 모니터링, 치료 효과 평가에 필수적인 역할을 하고 있습니다. 전 세계 인구의 고령화와 신경퇴행성 질환에 대한 인식이 높아지면서 정밀진단 툴에 대한 수요가 그 어느 때보다 높아지고 있습니다. 또한 제약 및 생명공학 기업은 맞춤형 의료를 위한 새로운 바이오마커를 발굴하기 위해 연구개발을 강화하고 있습니다. 표적치료에 대한 수요가 증가함에 따라 특히 신경퇴행성 질환과 정신질환 분야에서 바이오마커 발굴에 대한 투자가 확대되고 있습니다. 정밀의료가 확산됨에 따라 중추신경계 바이오마커는 치료 방침을 결정하고 환자의 예후를 개선하는 데 필수적인 요소로 자리 잡을 것으로 보입니다.

기술의 발전이 중추신경계 바이오마커 연구를 어떻게 강화하고 있는가?

유전체학, 단백질체학, 대사체학을 포함한 오믹스 기술의 혁신은 중추신경계 바이오마커 연구에 혁명을 불러일으키고 있습니다. 하이스루풋 시퀀싱과 첨단 분자 프로파일링 기술을 통해 보다 높은 특이성과 민감도로 새로운 바이오마커를 식별할 수 있습니다. 인공지능(AI)과 머신러닝도 방대한 데이터세트 분석에 적용되어 바이오마커를 기반으로 한 진단의 정확도가 향상되고 있습니다. 또한 액체생검 기술과 비침습적 뇌척수액(CSF) 바이오마커 분석의 인기가 높아지면서 신경질환을 검출하는 덜 침습적인 방법이 제공되고 있습니다. 웨어러블 바이오센서 및 원격 모니터링 툴을 포함한 디지털 헬스 기술의 통합은 바이오마커의 적용 범위를 확장하고 있습니다. 이러한 발전은 중추신경계 바이오마커의 상용화를 가속화하고, 신경질환 관리의 전반적인 효율성을 향상시킬 것으로 기대됩니다.

CNS 바이오마커의 성장을 가속하는 시장 동향은?

중추신경계 바이오마커 시장을 형성하는 주요 동향 중 하나는 바이오마커 기반 의약품 개발의 확대입니다. 제약사들은 약물의 효과와 환자 계층화를 개선하기 위해 임상시험에 바이오마커를 도입하는 경우가 늘고 있습니다. FDA 및 EMA와 같은 규제 당국도 바이오마커 검증 프로그램을 지원하여 보다 신속한 의약품 승인과 개인 맞춤형 치료 전략을 촉진하고 있습니다. 또 다른 큰 동향은 분자, 이미지, 디지털 바이오마커를 결합한 멀티모달 바이오마커 접근법의 부상입니다. PET, MRI 기반 바이오마커와 같은 신경영상 기술의 발전은 특히 알츠하이머병, 다발성 경화증과 같은 질환에서 질환의 진행을 보다 정확하게 시각화할 수 있게 해주고 있습니다. 또한 학계, 생명공학 기업, 의료기관의 협력은 혁신을 촉진하고 바이오마커의 발견과 검증을 가속화하고 있습니다.

중추신경계 바이오마커 시장의 주요 성장 촉진요인은?

중추신경계 바이오마커 시장의 성장은 신경계 질환의 부담 증가, 정밀의료 도입 확대, 바이오마커 탐색 기술 발전 등 여러 가지 요인에 의해 이루어지고 있습니다. 조기 진단 솔루션에 대한 수요 증가와 바이오마커 기반 의약품 개발 파이프라인의 확대는 시장 성장을 더욱 촉진하고 있습니다. 또한 바이오마커의 표준화 및 검증에 대한 규제 강화로 인해 제약회사들이 바이오마커를 임상시험에 통합하는 추세입니다. 특히 신경퇴행성 질환과 정신질환에서 바이오마커를 기반으로 한 동반진단의 확대는 시장 관계자들에게 새로운 비즈니스 기회를 제공합니다. 헬스케어 업계가 질병의 조기 발견과 개인 맞춤형 치료 전략에 대한 우선순위를 계속 높여가고 있는 가운데, 중추신경계 바이오마커 시장은 향후 수년간 지속적인 성장이 예상됩니다.

부문

바이오마커 유형(안전성, 유효성, 검증, 기타 바이오마커), 용도(질환 진단, Drug Discovery 개발, 개별화 치료, 기타 용도), 최종 용도(병원·진료소, 진단 연구소, 학술연구기관, 기타 최종 용도)

조사 대상 기업의 예

  • AbaStarMDx Inc.
  • AbbVie Inc.
  • Abcam plc
  • Abiant, Inc.
  • Agilent Technologies, Inc.
  • Avacta Group plc
  • Banyan Biomarkers
  • Biogen Inc.
  • Biohaven Pharmaceuticals
  • BioNTech SE
  • Bio-Rad Laboratories, Inc.
  • Biovista
  • BrainScope Company, Inc.
  • Charles River Laboratories International, Inc.
  • Diagenic ASA
  • EnCor Biotechnology
  • Enzo Biochem Inc.
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.11

Global Central Nervous System Biomarkers Market to Reach US$8.8 Billion by 2030

The global market for Central Nervous System Biomarkers estimated at US$5.9 Billion in the year 2024, is expected to reach US$8.8 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Safety Biomarker, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$4.6 Billion by the end of the analysis period. Growth in the Efficacy Biomarker segment is estimated at 6.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 11.1% CAGR

The Central Nervous System Biomarkers market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 11.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Central Nervous System Biomarkers Market - Key Trends & Drivers Summarized

Why Is the Demand for Central Nervous System Biomarkers Increasing?

The rising prevalence of neurological disorders such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and traumatic brain injuries is a significant factor driving the demand for central nervous system (CNS) biomarkers. These biomarkers play an essential role in early diagnosis, disease progression monitoring, and treatment efficacy assessment. With an aging global population and increasing awareness of neurodegenerative diseases, the need for precise diagnostic tools has never been higher. Additionally, pharmaceutical and biotechnology companies are intensifying their research and development (R&D) efforts to identify novel biomarkers for personalized medicine. The rise in demand for targeted therapies has prompted greater investments in biomarker discovery, particularly in the field of neurodegenerative and psychiatric disorders. As precision medicine gains traction, CNS biomarkers are set to become indispensable in guiding treatment decisions and improving patient outcomes.

How Are Technological Advancements Enhancing CNS Biomarker Research?

Innovations in omics technologies, including genomics, proteomics, and metabolomics, are revolutionizing CNS biomarker research. High-throughput sequencing and advanced molecular profiling techniques are enabling the identification of novel biomarkers with higher specificity and sensitivity. Artificial intelligence (AI) and machine learning are also being employed to analyze vast datasets, improving the accuracy of biomarker-based diagnostics. Moreover, liquid biopsy techniques and non-invasive cerebrospinal fluid (CSF) biomarker assays are gaining popularity, offering less invasive methods for detecting neurological diseases. The integration of digital health technologies, including wearable biosensors and remote monitoring tools, is expanding the scope of biomarker applications. These advancements are expected to accelerate the commercialization of CNS biomarkers and improve the overall efficiency of neurological disease management.

What Market Trends Are Driving the Growth of CNS Biomarkers?

The growing adoption of biomarker-driven drug development is one of the key trends shaping the CNS biomarker market. Pharmaceutical companies are increasingly incorporating biomarkers into clinical trials to improve drug efficacy and patient stratification. Regulatory agencies such as the FDA and EMA are also supporting biomarker validation programs, facilitating faster drug approvals and personalized treatment strategies. Another significant trend is the rise of multi-modal biomarker approaches that combine molecular, imaging, and digital biomarkers. Advances in neuroimaging techniques, such as PET and MRI-based biomarkers, are enabling more accurate visualization of disease progression, particularly in conditions like Alzheimer’s and multiple sclerosis. Additionally, collaborations between academia, biotech firms, and healthcare institutions are fostering innovation and accelerating biomarker discovery and validation.

What Are the Key Growth Drivers in the Central Nervous System Biomarkers Market?

The growth in the Central Nervous System Biomarkers market is driven by several factors, including the rising burden of neurological disorders, the growing adoption of precision medicine, and technological advancements in biomarker discovery. The increasing demand for early diagnostic solutions and the expansion of biomarker-based drug development pipelines are further fueling market growth. Moreover, regulatory push for biomarker standardization and validation is encouraging pharmaceutical companies to integrate biomarkers into clinical trials. The expansion of biomarker-based companion diagnostics, particularly in neurodegenerative and psychiatric disorders, is creating new opportunities for market players. As the healthcare industry continues to prioritize early disease detection and personalized treatment strategies, the CNS biomarker market is expected to experience sustained growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Central Nervous System Biomarkers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Biomarker Type (Safety Biomarker, Efficacy Biomarker, Validation Biomarker, Other Biomarkers); Application (Disease Diagnosis Application, Drug Discovery and Development Application, Personalized Medicines Application, Other applications); End-Use (Hospitals and Clinics, Diagnostic Laboratories End-Use, Academic and Research Institutes End-Use, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbaStarMDx Inc.
  • AbbVie Inc.
  • Abcam plc
  • Abiant, Inc.
  • Agilent Technologies, Inc.
  • Avacta Group plc
  • Banyan Biomarkers
  • Biogen Inc.
  • Biohaven Pharmaceuticals
  • BioNTech SE
  • Bio-Rad Laboratories, Inc.
  • Biovista
  • BrainScope Company, Inc.
  • Charles River Laboratories International, Inc.
  • Diagenic ASA
  • EnCor Biotechnology
  • Enzo Biochem Inc.
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Central Nervous System Biomarkers - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Neurological Disorders Propels Demand for Early and Accurate CNS Diagnostics
    • Technological Advancements in Imaging, Genomics, and Proteomics Drive Biomarker Discovery
    • Increased Investment in Neurodegenerative Disease Research Strengthens Pipeline for CNS Biomarkers
    • Regulatory Approvals and Companion Diagnostic Guidelines Spur Clinical Adoption of Biomarker Tests
    • Partnerships Between Biotech Firms and Academic Institutions Accelerate Translational Research
    • Growth in Personalized Medicine and Precision Neurology Expands Addressable Market for Biomarkers
    • Integration with Digital Health Tools and Wearable Devices Enhances Real-Time Monitoring Capabilities
    • Global Expansion of Biobanks and Patient Registries Facilitates Large-Scale Biomarker Validation
    • Pharmaceutical Interest in Biomarker-Based Drug Development Drives Market for Predictive Diagnostics
    • Clinical Utility in Treatment Response Monitoring Generates Demand for Longitudinal Biomarker Use
    • Quality Control and Standardization Issues Propel Innovation in Biomarker Assay Platforms
    • AI and Machine Learning in Biomarker Data Analysis Accelerate Insights and Clinical Decision Support
    • Expansion of Point-of-Care and Home-Based Testing Solutions Opens New Channels for Biomarker Utilization
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Central Nervous System Biomarkers Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Central Nervous System Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Central Nervous System Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Safety Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Safety Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Safety Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Efficacy Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Efficacy Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Efficacy Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Validation Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Validation Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Validation Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Disease Diagnosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Disease Diagnosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Disease Diagnosis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Drug Discovery & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Drug Discovery & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Drug Discovery & Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Personalized Medicines Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Personalized Medicines Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Personalized Medicines Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Other applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • CHINA
    • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Central Nervous System Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Central Nervous System Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Central Nervous System Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Central Nervous System Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • INDIA
    • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Central Nervous System Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Central Nervous System Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Central Nervous System Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Central Nervous System Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030
  • AFRICA
    • Central Nervous System Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Central Nervous System Biomarkers by Biomarker Type - Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Central Nervous System Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Safety Biomarker, Efficacy Biomarker, Validation Biomarker and Other Biomarkers for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Central Nervous System Biomarkers by End-Use - Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Central Nervous System Biomarkers by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Academic & Research Institutes End-Use, Other End-Users and Hospitals & Clinics for the Years 2015, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Central Nervous System Biomarkers by Application - Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Central Nervous System Biomarkers by Application - Percentage Breakdown of Value Sales for Disease Diagnosis Application, Drug Discovery & Development Application, Personalized Medicines Application and Other applications for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제